Tag - OTIC

Markets

Cantor cuts Otonomy PT to $6 from $13

Cantor Fitzgerald slashed its price target for Otonomy (NASDAQ:OTIC) to $6 from $13 but maintained its “overweight” rating, after the company announced that the Phase 3 study of OTIVIDEX in Ménière’s disease did not...

February 22, 2021

Developments

Otonomy completes enrollment in Phase 3 Meniere’s disease trial

Otonomy (NASDAQ:OTIC) completed enrollment in its Phase 3 study evaluating OTIVIDEX for the treatment of Meniere’s disease, a disorder of the inner ear that can lead to vertigo and hearing loss. The trial enrolled 149...

October 2, 2020

Developments

Otonomy starts Phase 1/2 trial of OTO-313 for tinnitus

Otonomy (NASDAQ:OTIC) initiated a Phase 1/2 trial of OTO-313, a novel formulation of gacyclidine, for the treatment of tinnitus. Patients with tinnitus experience noise or ringing in their ears. Otonomy notes that some...

April 11, 2019

Tag - OTIC

Cantor cuts Otonomy PT to $6 from $13

Otonomy completes enrollment in Phase 3 Meniere’s disease trial

Otonomy starts Phase 1/2 trial of OTO-313 for tinnitus

General

More